A preventive treatment for dementia may proceed to clinical trials after successful animal testing.
The US-led research is looking to develop effective immunotherapy via a new vaccine to remove ‘brain plaque’ and tau protein aggregates linked to Alzheimer’s disease.
Recent success in bigenic mice models supports progression to human trials in years to come, the researchers say.
A new paper in the journal Alzheimer’s Research & Therapy paves the way for more work in 2020, with medical researchers at the Institute for Molecular Medicine and University of California, Irvine (UCI) working with a successful vaccine formulated on adjuvant developed by Flinders University Professor Nikolai Petrovsky in South Australia.
The latest research aims to come up with a new treatment to remove accumulated beta-amyloid (A?) plaques and neurofibrillary tangles composed of hyperphosphorylated tau, which together lead to neurodegeneration and cognitive decline in Alzheimer’s disease.
Alzheimer’s disease (AD) is the leading cause of age-related dementia, affecting about 5.7 million people in the US. Major challenges in AD include the lack of effective treatments, reliable biomarkers, or preventive strategies.
Professor of the Institute for Molecular Medicine Anahit Ghochikyan and colleagues, Associate Professors Hvat Davtyan and Mathew Blurton-Jones from UCI, and other co-authors tested the universal MultiTEP platform-based vaccines formulated in the adjuvant developed at Professor Petrovsky’s Australian lab.
The possible new therapies were tested in bigenic mice with mix A? and tau pathologies.
“Taken together, these findings warrant further development of this dual vaccination strategy based on the MultiTEP technology for ultimate testing in human Alzheimer’s disease,” the lead authors Professor Ghochikyan and Blurton-Jones conclude.
Professor Petrovsky says the Advax adjuvant method is a pivotal system to help take the combination MultiTEP-based A?/tau vaccines therapy, as well as separate vaccines targeting these pathological molecules, to clinical trials – perhaps within two years.
“Our approach is looking to cover all bases and get past previous roadblocks in finding a therapy to slow the accumulation of A?/tau molecules and delay AD progression in a the rising number of people around the world,” says Professor Petrovsky, who will work in the US for the next three months.
Several promising drug candidates have failed in clinical trials so the search for new preventions or therapies continues.
A recent report on human monoclonal antibody, aducanumab, showed that high dose of this antibody reduced clinical decline in patients with early AD as measured by primary and secondary endpoints.
However, it is obvious that it could not be used as a preventive measure in healthy subjects due to the need for frequent (monthly) administration of high concentrations of immunotherapeutic.
Professor Ghochikyan says there is a pressing need to keep searching for new preventive vaccine to delay AD and slow down progression of this devastating disease.
The new combined vaccination approach could potentially be used to induce strong immune responses to both of the hallmark pathologies of AD in a broad population base of vaccinated subjects with high MHC (major histocompatibility complex) class II gene polymorphisms, the new paper concludes.
Learn more: Possible dementia vaccine closer after mice studies
Go deeper with Bing News on:
Dementia vaccine
- Study finds COVID-19 vaccine can help people with heart failure live longer
Heart failure patients who are vaccinated against COVID-19 have an 82% greater likelihood of living longer than those who are not vaccinated, according to research presented at Heart Failure 2024, a ...
- Scientists pinpoint new vaccine adjuvant that promotes potent anti-tumor immunity
Scientists from Trinity College Dublin have made an important breakthrough that offers promise for developing new immune therapies for cancer. They have discovered that a vaccine adjuvant called C100 ...
- Higher olive oil intake associated with lower risk of dementia-related death: JAMA
Researchers have found that higher olive oil intake is associated with a significantly lower risk of dementia-related mortality. This study was published in the journal JAMA Network Open by ...
- Dementia News
A Healthier Diet Is Linked With a Slower Pace of Aging, Reduced Dementia Risk, Study Shows Mar. 14, 2024 — A healthier diet is associated with a reduced dementia risk and slower pace of aging ...
- Olive oil could help reduce risk of dying from dementia, Harvard study says
Consuming olive oil could help reduce the risk of dying from dementia, regardless of overall diet quality, a new study in U.S. adults suggests.
Go deeper with Google Headlines on:
Dementia vaccine
[google_news title=”” keyword=”dementia vaccine” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Vaccine
- Will your last COVID vaccine work against new ‘FLiRT’ variants?
There are two new COVID-19 variants circulating, posing a threat to a summer surge. Is your last vaccine dose still protecting you?
- AstraZeneca Vaccine Withdrawal: Stop Acting As PROs For The Manufacturers - Kwesi Pratt Slams GHS
Kwesi Pratt has hurled tirade at the Ghana Health Service (GHS) for saying the withdrawal of the AstraZeneca Covid-19 vaccine is for commercial reasons. According to reports, AstraZeneca is withdrawing its Covid-19 vaccine worldwide,
Go deeper with Google Headlines on:
Vaccine
[google_news title=”” keyword=”vaccine” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]